Article metrics
PDF
Other content recommended for you
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance
- Changes to anti-JCV antibody levels in a Swedish national MS cohort
- Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
- MRI pattern in asymptomatic natalizumab-associated PML
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
- Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
- MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS